Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 571 participants.
Also called NCT03285594
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 571 participants
- Sponsor
- Registry
-
NCT03285594 -
2016-001804-43
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03285594. Randomized; double masking; primary purpose treatment. Start 2017-09-15 (actual); primary completion 2019-09-17 (actual). Results posted on 2021-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
- Acronym
- SOTA-INS
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Oral Antidiabetes Drugs (OADs)
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03285594- Content hash
4e05a69877c866e080be91349ec2fc7aa124d784fb8efe0627d816db5f133dbc